Related Experiment Video
Updated: Aug 2, 2026
11:02
Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing
Published on: October 18, 2013
19.9K
Next-generation sequencing-based genomic profiling of advanced soft tissue and bone sarcomas
Yasemin Gündoğdu1, Elif Şenocak Taşçı2, Leyla Özer3
1Department of Internal Medicine, Acıbadem MAA University, Istanbul, Türkiye.
Frontiers in Oncology
|October 20, 2025
Summary
Next-generation sequencing (NGS) identified actionable mutations in 22.2% of sarcoma patients, enabling targeted therapies. This highlights NGS
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- Sarcomas, rare mesenchymal tumors of soft tissue (STS) and bone, have limited treatment options and low survival rates for metastatic disease.
- Evidence for the clinical utility of next-generation sequencing (NGS) in sarcoma management remains limited.
- Current therapeutic strategies for sarcomas often fall short, especially in advanced stages.
Purpose of the Study:
- To identify targetable genomic alterations in sarcomas to guide treatment decisions.
- To explore the potential of next-generation sequencing (NGS) in uncovering therapeutic targets for rare cancers.
- To assess the feasibility of integrating genomic profiling into clinical practice for sarcoma patients.
Main Methods:
- Retrospective, multicenter analysis of 81 patients with STS and bone sarcomas.
- Next-generation sequencing (NGS) was performed using four different kits to investigate mutation profiles.
- Analysis focused on identifying actionable mutations and potential targeted therapies.
Main Results:
- Genomic alterations were detected in 90.1% of patients, with copy number amplifications (26.9%) and deletions (24.7%) being most common.
- Actionable mutations, eligible for FDA-approved therapies, were found in 22.2% of patients.
- The most frequent gene alterations involved TP53 (38%), RB1 (22%), and CDKN2A (14%). All patients were microsatellite stable.
Conclusions:
- Integrating NGS-derived genetic insights into clinical practice is crucial for improving sarcoma survival rates and treatment outcomes.
- NGS facilitates personalized therapeutic approaches by identifying targetable genomic alterations.
- NGS proved valuable as both a diagnostic tool, leading to reclassification in four patients, and for therapeutic decision-making.
Related Concept Videos
03:00Next-generation Sequencing
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
01:29Modern Molecular Taxonomy
Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...